Next Huge Biotech Stock is *** Echo Therapeutics (OTCBB: ECTE) ***

Echo Therapeutics is a transdermal medical device company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System as a platform technology for transdermal drug delivery.

ECTE believes that the Symphony tCGM System will change the paradigm of invasive, needle-based, pisodic glucose testing in the diabetes consumer and hospital critical care markets to one of continuous, eedle-free monitoring.

ECTE is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation to allow for transdermal drug delivery of a wide range of FDA-approved products.

ECTE believes that the Symphony system is an ideal solution for diabetics and critically ill patients allowing for continuous, pain-free monitoring of glucose levels.

The continuous monitoring will enable more accurate management of diabetes (resulting in healthier outcomes) and higher compliance compared to painful, invasive methods for drawing blood today.

ECTE also believes that its Prelude SkinPrep System will allow many drugs currently delivered by needle injection to be administered without a needle by using Prelude prior to transdermal drug administration.

----------------------------------

ECTE's $15 Million Agreement

ECTE has signed a $15 million agreement, giving Ferndale Pharmaceuticals a license to develop, market and sell Prelude for enhanced delivery of Ferndale’s topical lidocaine product, LMX4, in North America and the UK. Echo received $750,000 up front and will receive $750,000 upon FDA approval, as well as $12.5 million in milestones and guaranteed minimum royalty payments. Echo will also receive a double digit royalty on
net sales of the product.

------------------------------------------------

What is the Symphony™ tCGM System?

• Non-invasive, wireless, continuous blood glucose monitoring system
• Utilizes Prelude™ SkinPrep, a novel, needle-free platform technology that increases skin permeability
• Efficient, remote monitoring platform compared to platforms using needle-basedtechnologies for accuracy
• Low manufacturing cost and a razor/razor blade model with a single-use consumable
• Readings obtained every minute with wireless data transmission to portable monitor
• Short, one-hour warm-up

----------------------------------------------------

Product Pipeline

• Six consecutive positive pilot studies in glucose monitoring to date
• 510-k filing in 1Q10 for Prelude with the use of lidocaine
• Prelude lidocaine sales offer best near-term revenue opportunity
• Minimum sales would reduce cash burn and move company toward cash flow positive business
• Revenues projected to begin during 2Q10
• Pivotal trial and PMA filing for Symphony™ anticipated in 2010 for glucose monitoring
• Symphony™ tCGM licensed in South Korea to Handok Pharmaceuticals

---------------------------------------------

ECTE Could Be a High Growth Top-Shelf Pharmaceutical/Biotech Stock

I've mentioned that there are some stocks that perform extremely well because they are "Story Stocks" whose one-of-a-kind, unique technology is intriguing and special enough that it makes entertaining discussions for those not even involved in development-stage companies that are abundant in the OTC/OTCBB Markets.

And, there are other stocks that have highly compelling reasons from a technical viewpoint that suggest a profitable breakout could put traders into outstanding profit positions.

So, how does this relate to Echo Therapeutics (OTCBB: ECTE)? Simple...I believe that ECTE has both categories of trading philosophies in its corner, and that could be the ingredients for an explosive opportunity wherein the symbol could absolutely soar!

Watch ECTE trade...don't miss out!